Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs;Drogas antituberculose: Interações medicamentosas, efeitos adversos e utilização em situações especiais. parte 1: Fármacos de primeira linha

Jornal Brasileiro de Pneumologia

Volumn 36, Issue 5, 2010, Pages 626-640

  Arbex, Marcos Abdo ^a,b   Varella, Marília de Castro Lima ^c   de Siqueira, Hélio Ribeiro ^d   de Mello, Fernando Augusto Fiúza ^e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital Nestor Goulart Reis   (Brazil)

^c UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

^d STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e Secretary of Health of Sa o Paulo State   (Brazil)

Author keywords

Antibiotics; Antitubercular; Drug interactions; Drug toxicity; Drug induced liver injury; Pharmacologic actions; Tuberculosis

Indexed keywords

EID: 78649423842     PISSN: 18063713     EISSN: 18063713     Source Type: Journal    
DOI: 10.1590/s1806-37132010000500016     Document Type: Review

References (63)

1. Ministério da Saúde. Secretária de Vigilância em Sau ́de. Departamento de Vigilância Epidemiológica. Programa Nacional de Controle da Tuberculose. Nota técnica sobre as mudanças no tratamento da tuberculose no Brasil para adultos e adolescentes - versão 2. Brasília: Ministério da Saúde; 2009.
2. Conde MB, Melo FA, Marques AM, Cardoso NC, Pinheiro VG, Dalcin Pde T, et al. III Brazilian Thoracic Association Guidelines on tuberculosis. J Bras Pneumol. 2009;35(10):1018-1048.
3. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-662.
4. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update 2008. Geneva: World Health Organization, Stop TB Department; 2008.
5. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. Geneva: World Health Organization; 2003.
6. Pai MP, Momary KM, Rodvold KA. Antibiotic drug interactions. Med Clin North Am. 2006;90(6):1223-1255.
7. Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Centro de Referência Professor Hélio Fraga; Sociedade Brasileira de Pneumologia e Tisiologia. Controle da tuberculose: uma proposta de integração ensino-serviço. Rio de Janeiro: FUNASA/CRPHF/SBPT; 2002.
8. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9(10):2026-2030.
9. Javadi MR, Shalviri G, Gholami K, Salamzadeh J, Maghooli G, Mirsaeedi SM. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol Drug Saf. 2007;16(10):1104-1110.
10. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472-1477.
11. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61(9):791-794.
12. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis. 2007;11(12):1314-1320.
13. Gholami K, Kamali E, Hajiabdolbagh Mi, Shalviri G. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharm Pract. 2006;4(3):134-138.
14. Vieira DE, Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil. J Bras Pneumol. 2008;34(12):1049-1055.
15. Zhang Y. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-564.
16. Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008;88(2):112-116.
17. Slayden RA, Barry CE. The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis. Microbes Infect. 2000;2(6):659-669.
18. Srivastava A, Maggs JL, Antoine DJ, Williams DP, Smith DA, Park BK. Role of reactive metabolites in drug-induced hepatotoxicity. Handb Exp Pharmacol. 2010;(196):165-194.
19. Baghaei P, Tabarsi P, Chitsaz E, Saleh M, Marjani M, Shemirani S, et al. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am J Ther. 2010;17(1):17-22.
20. Gupta NK, Lewis JH. Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther. 2008;28(9):1021-1041.
21. Bliven EE, Podewils LJ. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. Int J Tuberc Lung Dis. 2009;13(9):1054-1060.
22. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis. 1989;140(3):700-705.
23. Silva Jr JB. Tuberculose: Guia de vigilância epidemiológica. J Bras Pneumol. 2004;30(Suppl 1):S57-S86.
24. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009;59(3):167-187.
25. Tajender V, Saluja J. INH induced status epilepticus: response to pyridoxine. Indian J Chest Dis Allied Sci. 2006;48(3):205-206.
26. Tai WP, Yue H, Hu PJ. Coma caused by isoniazid poisoning in a patient treated with pyridoxine and hemodialysis. Adv Ther. 2008;25(10):1085-1088.
27. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5(2):231-249.
28. Nisar M, Watkin SW, Bucknall RC, Agnew RA. Exacerbation of isoniazid induced peripheral neuropathy by pyridoxine. Thorax. 1990;45(5):419-420.
29. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301(1):99-105.
30. Rakotoson JL, Randriamanana D, Rakotomizao JR, Andrianasolo R, Rakotoarivelo R, Andrianarisoa AC. Severe systemic lupus erythematosus induced by isoniazid [Article in French]. Rev Pneumol Clin. 2009;65(6):361-364.
31. Nardiello S, Pizzella T, Ariviello R. Risks of antibacterial agents in pregnancy [Article in Italian]. Infez Med. 2002;10(1):8-15.
32. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776-789.
33. Sun HY, Chen YJ, Gau CS, Chang SC, Luh KT. A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. J Formos Med Assoc. 2009;108(2):102-111.
34. Vikrant S, Agarwal SK, Gupta S, Bhowmik D, Tiwari SC, Dash SC, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis. 2005;7(3-4):99-108.
35. Caminero Luna JA. Guía de la Tuberculosis para Médicos Especialistas. Paris: Unión Internacional Contra la Tuberculosis y Enfermedades Respiratorias; 2003.
36. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother. 2001;45(2):382-392.
37. Campos-Franco J, González-Quintela A, Alende-Sixto MR. Isoniazid-induced hyperacute liver failure in a young patient receiving carbamazepine. Eur J Intern Med. 2004;15(6):396-397.
38. Self TH, Chrisman CR, Baciewicz AM, Bronze MS. Isoniazid drug and food interactions. Am J Med Sci. 1999;317(5):304-311.
39. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998;79(1):3-29.
40. Petri, WA. Quimioterapia da tuberculose, complexo Mycobacterium avium e hanseníase. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman - As Bases Farmacológicas da Terapêutica. Rio de Janeiro: McGraw-Hill; 2006. p. 1083-1101.
41. Wallace, Jr RC, Griffith DE. Antimycobacterial agents. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia: Churchill Livingstone/ Elsevier; 2009. p. 533-548.
42. Chouraqui JP, Bessard G, Favier M, Kolodie L, Rambaud P. Haemorrhage associated with vitamin K deficiency in pregnant women and newborns. Relationship with rifampicin therapy in two cases [Article in French]. Therapie. 1982;37(4):447-450.
43. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008;335(2):126-136.
44. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819-850.
45. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737-746.
46. Kwara A, Ramachandran G, Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol. 2010;6(1):55-68.
47. Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf. 2002;25(2):111-133.
48. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med. 1984;311(26):1681-1683.
49. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 1998;53(7):536-548.
50. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13(11):1320-1330.
51. World Health Organization. The Treatment of Tuberculosis Guidelines. Geneva: World Health Organization; 2010.
52. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res. 2001;2(3):164-168.
53. Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008;88(2):141-144.
54. Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008;88(2):102-105.
55. Citron KM, Thomas GO. Ocular toxicity from ethambutol. Thorax. 1986;41(10):737-739.
56. Chan RY, Kwok AK. Ocular toxicity of ethambutol. Hong Kong Med J. 2006;12(1):56-60.
57. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med. 1999;159(5 Pt 1):1580-1584.
58. Migliori GB, D'Arcy Richardson M, Sotgiu G, Lange C. Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control. Clin Chest Med. 2009;30(4):637-665, vii.
59. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935-952.
60. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006;11(6):699-707.
61. Tost JR, Vidal R, Caylà J, Díaz-Cabanela D, Jiménez A, Broquetas JM, et al. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis. 2005;9(5):534-540.
62. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192-202.
63. Chang KS. Treatment of tuberculosis in presence of hepatic and renal impairment. Respirology. 2008;13(Suppl 3):S100-S107.